Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer

Figure 1

Androgen dependent and independent molecular pathways underlying progression of castration refractory prostate cancer and drugs targeting those pathways. CYP17: Cytochrome P450 17 alpha-hydroxylase and C17,20-lyase; mCRPC: metastatic castration refractory prostate cancer; AR: androgen receptor; OS: overall survival; PFS: progression free survival; c-MET: hepatocyte growth factor receptor; VEGF: vascular endothelial growth factor; MeTr: DNA methyl transferase; HDAC: histone deacetylases; Src: Src kinase; MAPK: MAP kinase; IGF-1: insulin like growth factor-1.